ClinicalTrials.gg
RecruitingNCT07717411PrevenTRONUpdated Nov 6, 2026

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

A Phase 3 interventional study of Trontinemab and Placebo in Alzheimer's Disease, sponsored by Hoffmann-La Roche. Recruiting at 72 sites in 10 countries. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 6, 2026First sites in 6 new countriesStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,600
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Alzheimer Disease by Hoffmann-La Roche — 3 open to participants now, 8 under way, 4 of them phase 3. Alzheimer Disease · Hoffmann-La Roche.

Planned enrollment
2nd of 40
1,600 · median 247
Started
2026
with 2 others
Phase 3
14 of 40
2 open now
Registered
39th of 40
by date

Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2026, is one of 14 in phase 3, and was the 39th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 40 studies in Alzheimer Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Alzheimer Disease by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's
  • Alzheimer's Disease
  • pre-clinical
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight of 150 kg or less
  • Willingness and ability to complete all aspects of the study for the duration of the study
  • Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted)
  • Cognitively and functionally unimpaired as defined by the protocol
  • Availability of a study partner as defined by the protocol
  • A plasma pTau217 level consistent with a high likelihood of future clinical progression

Exclusion criteria

Exclusion Criteria:

  • Any evidence of a condition other than AD that may affect cognition, including, but not limited to, frontotemporal dementia, dementia with Lewy bodies, vascular dementia, Parkinson disease, corticobasal syndrome, Creutzfeldt-Jakob disease, progressive supranuclear palsy, frontotemporal lobar degeneration (other than frontotemporal dementia), Huntington disease, normal pressure hydrocephalus, seizure disorder, delirium, or hypoxia
  • Mild cognitive impairment (MCI; may be referred to as prodromal AD), or any form of dementia
  • History or presence of cerebrovascular disease
  • History of severe, clinically significant (persistent neurologic deficit or structural brain damage) central nervous system (CNS) trauma
  • History or presence of clinically significant intracranial mass
  • History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder
  • History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 12 months of an acute event that is consistent, in the opinion of the PI, with a
  • At risk for suicide in the opinion of the investigator
  • Substance abuse disorder within 12 months prior to screening (nicotine use is allowed)
  • Any other medical conditions (e.g., cardiovascular, hepatic, renal disease) which are not stable and adequately controlled or which in the opinion of the investigator could affect the participant's safety in the study or interfere with the study assessments
  • Uncontrolled hypertension
  • Impaired hepatic function
  • History or presence of any clinically significant hematological diseases
  • Diagnosis of a wet age-related macular degeneration (AMD)
  • Abnormal thyroid function
  • Abnormally low serum levels of folic acid or vitamin B12 deficiency that are judged to be clinically significant and/or may impact cognition as per the investigator's judgment
  • Current , , or infection that has not been adequately treated in the opinion of the investigator
  • History of
  • Any previous administration of active immunotherapy (vaccine) that is being evaluated to prevent or postpone cognitive decline
  • Any previous or current use of passive immunotherapy (immunoglobulin) or other long-acting biologic agent that is approved or under evaluation or has been evaluated to prevent or postpone cognitive decline
  • Any other treatment within 5 half-lives or 4 months prior to screening, whichever is longer
  • Intravenous (IV) or subcutaneous immunoglobulin therapy within 5 half-lives or 4 months prior to baseline whichever is longer
  • Anticoagulation medications at screening and there should be no plans to initiate any prior to or after randomization
  • Any treatment with cholinesterase inhibitors
  • Antipsychotic or neuroleptic medications within 3 months of screening, except as brief treatment for a non-psychiatric indication
  • Individuals with chronic use of opiates or opioids, benzodiazepines, barbiturates, or hypnotics, antidepressants or medication to treat anxiety should be on a stable dose for at least 8 weeks before baseline
  • Currently enrolled in an interventional study including those requiring investigational medicinal product (IMP) or involving any type of medical research that may interfere with study cognitive assessments
  • Residence in a skilled nursing facility such as a convalescent home or long-term care facility
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,600 participants (estimated)

Study arms

  • Experimental
    Trontinemab

    Participants will receive intravenous (IV) trontinemab.

    Drug: Trontinemab

  • Placebo comparator
    Placebo

    Participants will receive IV placebo.

    Drug: Placebo

Interventions

  • Participants will receive IV trontinemab.

  • DrugPlacebo

    Participants will receive IV placebo.

06

What researchers measure

Primary outcomes

  1. Time to Progression, defined as confirmed Clinical Dementia Rating - Global Score (CDR-GS) > 0

    Time frame: Baseline up to approximately 6 years

Secondary outcomes

  1. Change from Baseline through Week 216 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)

    Time frame: Baseline through Week 216

  2. Change from Baseline through Week 216 in Free and Cued Selective Reminding Test (FCSRT) total recall score

    Time frame: Baseline through Week 216

  3. Change from Baseline through Week 216 in Digit Symbol Substitution Test (DSST) coding score

    Time frame: Baseline through Week 216

  4. Change from Baseline through Week 216 in Cognitive Function Instrument (CFI) study partner, total score

    Time frame: Baseline through Week 216

  5. Change from Baseline through Week 216 in Category fluency total score

    Time frame: Baseline through Week 216

  6. Change from Baseline through Week 216 in Mini-Mental State Examination (MMSE) total score

    Time frame: Baseline through Week 216

  7. Change from Baseline through Week 216 in Wechsler Memory Scale, Logical Memory II Delayed Paragraph Recall (WMS LM II [DR]) score

    Time frame: Baseline through Week 216

  8. Change from Baseline through Week 216 in Amsterdam Instrumental Activities of Daily Living Questionnaire-Short Version (A-IADL-Q-SV) study partner, total score

    Time frame: Baseline through Week 216

  9. Change from Baseline through Week 216 in Trail Making Test (TMT)

    Time frame: Baseline through Week 216

  10. Time to progression to adjudicated mild cognitive impairment (MCI) diagnosis

    Time frame: Baseline up to approximately 6 years

  11. Incidence of adverse events

    Time frame: Baseline up to approximately 6 years

  12. Frequency of amyloid-related imaging abnormalities-edema/effusion (ARIA-E) and amyloid-related imaging abnormalities-hemosiderin deposition (ARIA-H) magnetic resonance imaging (MRI) findings

    Time frame: Baseline up to approximately 6 years

  13. Severity of ARIA-E and ARIA-H MRI findings

    Time frame: Baseline up to approximately 6 years

  14. Frequency of infusion-related reactions (IRRs)

    Time frame: Baseline up to approximately 6 years

  15. Severity of IRRs

    Time frame: Baseline up to approximately 6 years

  16. Incidence of anti-drug antibodies (ADAs) to trontinemab

    Time frame: Baseline up to approximately 6 years

  17. Change from baseline through Week 216 in brain amyloid load, as measured by amyloid positron emission tomography (PET) scan

    Time frame: Baseline through Week 216

  18. Change from baseline through Week 216 in blood biomarker phosphorylated tau 217 (pTau217)

    Time frame: Baseline through Week 216

  19. Change from baseline through Week 216 in blood biomarker glial fibrillar acidic protein (GFAP)

    Time frame: Baseline through Week 216

07

Study locations

72 of 72 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2032, 69 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 69 months is above that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Nov 2026 → Oct 2026 and primary completion Sep 2032 → Jul 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 21, 2026
StartActual
Oct 2, 2026was Nov 2026
Primary completionEst.
Jul 30, 2032was Sep 2032
CompletionEst.
Sep 3, 2032
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
65 sites added — first sites in Argentina, Australia, Taiwan, Brazil, Chile and 1 more
All 6 countries

Argentina, Australia, Taiwan, Brazil, Chile, Japan

Show 65 added (20 United States, 17 China, 7 Japan, 6 United Kingdom, 5 Canada, 3 Taiwan, 2 Argentina, 2 Australia, 2 Brazil, 1 Chile)
  • Healthy Brain Clinic · Long Beach, United States
  • Oakland Clinical · Oakland, United States
  • Renstar Medical Research · Ocala, United States
  • Charter Research - Winter Park/Orlando · Orlando, United States
  • Conquest Research - Lake Nona · Orlando, United States
  • Charter Research - Lady Lake/The Villages · The Villages, United States
  • Conquest Research, LLC · Winter Park, United States
  • Sana Research, LLC · Arlington, United States
  • Hospital Italiano de Buenos Aires · Buenos Aires, Argentina
  • Royal Prince Alfred Hospital · Camperdown, Australia
  • KaRa Institute of Neurological Diseases · Macquarie Park, Australia
  • Kelowna Health and Memory Centre Ltd. · Kelowna, Canada
  • The second Affiliated Hospital of Guangzhou Medical University · Guangzhou, China
  • The First Hospital of Hebei Medical University · Shijiazhuang, China
  • Yan'an University Xianyang Hospital · Xianyang, China
  • Beijing Friendship Hospital Affiliated of Capital University of Medical Science · Beijing, China
  • Sir Run Run Shaw Hospital Zhejiang University · Hangzhou, China
  • The Second Affiliated Hospital of Nanjing Medical University · Nanjing, China
  • Nanjing First Hospital · Nanjing, China
  • The Second Affiliated Hospital of Suzhou University · Suzhou, China
  • Taipei Veterans General Hospital · Taipei, Taiwan
  • Scottish Brain Sciences · Aberdeen, United Kingdom
  • Re:Cognition Health Birmingham · Birmingham, United Kingdom
  • Scottish Brain Sciences · Edinburgh, United Kingdom
  • Re:Cognition Health London · London, United Kingdom
  • Charing Cross Hospital · London, United Kingdom
  • Moorgreen Hospital · Southampton, United Kingdom
  • Inglewood Clinicals · Los Angeles, United States
  • Riverside Clinical · Riverside, United States
  • Cenexel California Neuroscience Research, LLC · Sherman Oaks, United States
  • …and 35 more on the registry record
across 2 updates, Oct 13, 2026 – Nov 6, 2026
Start date
Nov 30, 2026→Oct 2, 2026 (actual)
Nov 6, 2026
Primary completion
Sep 3, 2032→Jul 30, 2032
Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    38 sites added — first sites in Brazil, Chile and Japan
    Show 38 added (12 United States, 9 China, 7 Japan, 4 Canada, 2 Brazil, 2 Taiwan, 1 Argentina, 1 Chile)
    • Inglewood Clinicals · Los Angeles, United States
    • Riverside Clinical · Riverside, United States
    • Cenexel California Neuroscience Research, LLC · Sherman Oaks, United States
    • Alzheimer's Research and Treatment Center · Stuart, United States
    • Alzheimer?s Research and Treatment Center · Wellington, United States
    • Alzheimer's Research and Treatment Center - Columbus · Columbus, United States
    • Hawaii Pacific Neuroscience · Honolulu, United States
    • Great Lakes Clinical Trials Chicago d/b/a Flourish Research Andersonville · Chicago, United States
    • Adams Clinical Boston · Boston, United States
    • Boston Center for Memory · Newton, United States
    • Adams Clinical Watertown · Watertown, United States
    • National Clinical Research Inc.-Richmond · Richmond, United States
    • INECO Neurociencias Orono · Rosario, Argentina
    • Hospital Moinhos de Vento · Porto Alegre, Brazil
    • Hospital das Clinicas - UFRGS · Porto Alegre, Brazil
    • Kawartha Regional Memory Clinic · Peterborough, Canada
    • Centricity Research Toronto · Toronto, Canada
    • Genge Partners Inc. · Montreal, Canada
    • Alpha Recherche Clinique · Québec, Canada
    • Clínica MEDS · Santiago, Chile
    • the First Hospital of Jilin University · Changchun, China
    • Peking University First Hospital · Beijing, China
    • Fujian Medical University Union Hospital · Fuzhou, China
    • Guangdong Provincial People's Hospital · Guangzhou, China
    • The Second Affiliated Hospital of Nanchang University · Nanchang, China
    • Nanjing Brain Hospital · Nanjing, China
    • Tongji Hospital of Tongji University · Shanghai, China
    • Shaanxi Provincial People's Hospital · Xi'an, China
    • The First Affiliated Hospital of Xi'an Medical University · Xi'an, China
    • National Center for Geriatrics and Gerontology · Aichi, Japan
    • …and 8 more on the registry record
    Start date Nov 30, 2026→Oct 2, 2026 (now actual)
    Primary completion Sep 3, 2032→Jul 30, 2032
    + 1 other change: verification date
  2. Oct 13, 2026
    27 sites added — first sites in Argentina, Australia and Taiwan
    Show 27 added (8 United States, 8 China, 6 United Kingdom, 2 Australia, 1 Argentina, 1 Canada, 1 Taiwan)
    • Healthy Brain Clinic · Long Beach, United States
    • Oakland Clinical · Oakland, United States
    • Renstar Medical Research · Ocala, United States
    • Charter Research - Winter Park/Orlando · Orlando, United States
    • Conquest Research - Lake Nona · Orlando, United States
    • Charter Research - Lady Lake/The Villages · The Villages, United States
    • Conquest Research, LLC · Winter Park, United States
    • Sana Research, LLC · Arlington, United States
    • Hospital Italiano de Buenos Aires · Buenos Aires, Argentina
    • Royal Prince Alfred Hospital · Camperdown, Australia
    • KaRa Institute of Neurological Diseases · Macquarie Park, Australia
    • Kelowna Health and Memory Centre Ltd. · Kelowna, Canada
    • The second Affiliated Hospital of Guangzhou Medical University · Guangzhou, China
    • The First Hospital of Hebei Medical University · Shijiazhuang, China
    • Yan'an University Xianyang Hospital · Xianyang, China
    • Beijing Friendship Hospital Affiliated of Capital University of Medical Science · Beijing, China
    • Sir Run Run Shaw Hospital Zhejiang University · Hangzhou, China
    • The Second Affiliated Hospital of Nanjing Medical University · Nanjing, China
    • Nanjing First Hospital · Nanjing, China
    • The Second Affiliated Hospital of Suzhou University · Suzhou, China
    • Taipei Veterans General Hospital · Taipei, Taiwan
    • Scottish Brain Sciences · Aberdeen, United Kingdom
    • Re:Cognition Health Birmingham · Birmingham, United Kingdom
    • Scottish Brain Sciences · Edinburgh, United Kingdom
    • Re:Cognition Health London · London, United Kingdom
    • Charing Cross Hospital · London, United Kingdom
    • Moorgreen Hospital · Southampton, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07717411
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Oct 2, 2026
Primary completion
Jul 30, 2032 (estimated)
Completion
Sep 3, 2032 (estimated)
Last update
Nov 6, 2026

Study contacts

Reference Study ID Number: WN46072 https://forpatients.roche.com
Contact
global-roche-genentech-trials@gene.com
1-888-662-6728
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trontinemab

Start the discussion